Imatinib Mesylate: A Review of Its Use in Chronic Myeloid Leukemia

American Journal of Cancer

Volumn 2, Issue 6, 2003, Pages 439-454

  Curran, Monique P ^a   Croom, Katherine F ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANTIHISTAMINIC AGENT; BCR ABL PROTEIN; BCR ABL PROTEIN TYROSINE KINASE; BUSULFAN; CALCIUM; CYTARABINE; CYTOCHROME P450 3A4; CYTOCHROME P450 ACTIVATOR; CYTOCHROME P450 INHIBITOR; DAUNORUBICIN; DIURETIC AGENT; DOXORUBICIN; DRUG METABOLITE; ENZYME ACTIVATOR; ERYTHROMYCIN; ETOPOSIDE; HYDROXYUREA; IMATINIB; KETOCONAZOLE; MAGNESIUM; ONDANSETRON; OROSOMUCOID; PHENYTOIN; PIPERAZINE DERIVATIVE; PROCHLORPERAZINE; PROTEIN TYROSINE KINASE; STEROID; UNCLASSIFIED DRUG;

ANOREXIA; ARTHRALGIA; BLAST CELL CRISIS; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; GENE OVEREXPRESSION; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; POINT MUTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 0742320300     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200302060-00005     Document Type: Review

References (90)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 Apr 29; 340: 1330-40
2. Griffin J. The biology of signal transduction inhibition: basic science to novel therapies. Semin Oncol 2001 Oct; 28 (5 Suppl. 17): 3-8
3. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001 Aug 22; 286: 895-8
4. Savage DG, Antman KH. Imatinib mesylate: a new oral targeted therapy. N Engl J Med 2002 Feb 28; 346 (9): 683-93
5. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000 Nov 15; 96 (10): 3343-56
6. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003 Jan; 40 (1): 79-86
7. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 May; 2: 561-6
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 Oct; 295 (1): 139-45
9. Okuda K, Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activity is inhibited by ST1571. Blood 2001; 97 (8): 2440-8
10. Lyseng-Williamson K. Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765-74
11. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 2003; 63 (5): 513-22
12. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997 Dec 15; 90: 4947-52
13. Buchdunger E, Zimmerman J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56: 100-4
14. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23 (19): 380-94
15. Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997 Nov 1; 90 (9): 3691-8
16. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing 190-KD BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148) [abstract]. Blood 1997 Nov 15; 90 (Suppl. 1, Pt 1): 248a
17. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999 Jan 20; 91 (2): 163-8
18. Kawaguchi Y, Jinnai I, Nagai K, et al. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia 2001 Apr; 15: 590-4
19. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002 Mar; 117 (3): 360-7
20. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002 Jul 15; 100 (2): 435-41
21. Topaly J, Zeller WJ, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002 Oct; 119 (1): 3-14
22. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85
23. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 Aug 3; 293 (5531): 876-80
24. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95: 1758-66
25. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002 May 1; 99 (9): 3472-5
26. von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002 Feb 9; 359: 487-91
27. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 Aug; 2 (2): 117-25
28. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-6
29. Holtz MS, Slovak ML, Zhang F, et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002 May 15; 99 (10): 3792-800
30. Marley SB, Deininger MWN, Davidson RJ, et al. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granolocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000 May; 28: 551-7
31. Marley SB, Davidson RJ, Lewis JL, et al. Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo. Leuk Res 2001 Nov; 25 (11): 997-1002
32. Druker BJ, Sawyers CL, Capdeville R, et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001; 87-112
33. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21 (8): 1637-47
34. Mahon FX, Deininger MWN, Schultheis B. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 2000; 96 (3): 1070-9
35. + cells obtained from leukemic patients. Blood Cells Mol Dis 2002 May 30; 28 (3): 361-72
36. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. α1 Acid glycoprotein binds to imatinib (ST1571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003 Feb; 9 (2): 625-32
37. Novartis Pharmaceuticals Corporation. Gleevec™ imatinib mesylate: full prescribing information. East Hanover (NJ): Novartis, 2002 Feb
38. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031-7
39. Reckmann AH, Fischer T, Peng B, et al. Effect of food on STI571 Glivec pharmacokinetics and bioavailability [abstract 1223]. Proceedings of the 37th Annual Meeting of the American Society of Clinical Oncology; 2001 May 12-15; San Francisco, CA; 20 (Pt 1): 307a
40. Leis JF, Stepan DE, Curtin PT, et al. Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL [abstract no. 590]. Blood 2001; 98 (11 Pt 1): 140a
41. O'Brien SG, Peng B. Dutreix C, et al. A pharmacokinetic interaction of Glivec® and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia [abstract no. 593]. Blood 2001; 98 (11 Pt 1): 141a
42. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 (11): 994-1004
43. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 May 15; 99: 3530-9
44. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 Mar 15; 99 (6): 1928-37
45. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346 (9): 645-52
46. Bassi S, Trabacchi E, Bonifazi F, et al. Imatinib (Glivec®) in patients with Ph+ chronic myeloid leukemia in chronic phase after interferon failure: results of a phase II trial of the Italian Cooperative Study Group on CML [abstract no. 3096]. Blood 2002; 100 (Pt 1): 783a
47. Cortes JE, Talpaz M, O'Brien S, et al. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily [abstract no. 350]. Blood 2002 Nov 16; 100 (11 Pt 1): 95a
48. Trabacchi E, Bonifazi F, Bassi S, et al. Imatinib (Glivec®) in patients with Ph+ chronic myeloid leukemia in accelerated/blastic phase (AP/B): results of a phase II trial of the Italian Cooperative Study Group on CML (ICSG on CML) [abstract no. 2295]. Blood 2002; 100 (Pt 1): 584a
49. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 May 15; 99 (10): 3547-53
50. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 Apr 5; 344 (14): 1038-42
51. Arthur C, Fay K, Grigg A. et al. Imatinib treatment for advanced CML improves patients' quality of life [abstract no. 4859]. Blood 2002 Nov 16; 100 (Pt 2): 327b
52. Hughes T, Kaeda J, Branford S, et al. Molecular responses to imatinib (ST1571) or interferon + Ara-C as initial therapy for CML; results in the IRIS Study [abstract no. 345]. Blood 2002 Nov 16; 100 (Pt 1): 93a-4a
53. Lange T, Niederwieser DW. Residual disease in chronic myeloid leukemia after induction of molecular remission. N Eng J Med 2003; 349 (15): 1483-4
54. Hahn EA, Sorensen MV, Hudgens SA, et al. Quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS Study of interferon-alpha plus Ara-C vs imatinib (STI571, Glivec®, Gleevec™) [abstract no. 346]. Blood 2002 Nov 16; 100 (Pt 1): 94a
55. Reed SD, Radeva JI, Glendenning A, et al. Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-α) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase [abstract no. 698]. Blood 2002 Nov 16; 100 (Pt 1): 187a
56. Hensley ML, Van Hoomissen IC, Krahnke T, et al. Imatinib in chronic myeloid leukemia (CML): outcomes in >7000 patients treated on expanded access program (EAP) [abstract no. 2328]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago, 579
57. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Huntingt) 1999 Feb; 13 (2): 169-80; discussion 181, 184
58. National Cancer Institute. Common Toxicity Criteria, Version 2.0 1999 Jun 1 [online]. Available from URL: http://ctep.cancer.gov [Accessed 2003 Mar 30]
59. Novartis International AG. Data prove Glivec® is superior treatment for patients newly diagnosed with chronic myeloid leukemia [online]. Available from URL: http://www.novartis.com [Accessed 2002 Apr 5]
60. FDA. FDA approves gleevec for pediatric leukemia treatment [online]. Available from URL: http://www.fda.gov [Accessed 2003 Sep 10]
61. O'Dwyer M. Current use of imatinib in the treatment of chronic myeloid leukemia. Haematologica 2003 Mar; 88 (3): 241-4
62. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348 (11): 1048-50
63. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001 Oct 1; 98 (7): 2039-42
64. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999 Sep 1; 94 (5): 1517-36
65. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994 Mar 24; 330 (12): 820-5
66. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-α n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995 Jun 3; 345 (8962): 1392-7
67. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: J Natl Cancer Inst 1997 Nov 5; 89 (21): 1616-20
68. Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-α 2b for chronic myeloid leukemia. Blood 1998 Apr 15; 91 (8): 2713-21
69. Guilhot F, Chastang C, Michallet M. et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997 Jul 24; 337 (4): 223-9
70. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999 Dec 15; 86 (12): 2632-41
71. Mauro MJ, Kurilik G, Balleisen S, et al. Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy [abstract no. 584]. Blood 2001; 98: 139a
72. Goldman J. Implications of imatinib mesylate for hematopoietic stem cell transplantation. Semin Hematol 2001 Jul; 38 (3 Suppl. 8): 28-34
73. Sausville EA. Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard? Lancet 2003; 361: 1400-1
74. Cervantes F, Hernández-Boluda J-C, Odriozola J. et al. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. Br J Haematol 2003 Feb; 120 (3): 500-4
75. Hess G, Siegert W, Kolb HJ, et al. A phase II open-label study to investigate the safety profile and potential of imatinib mesylate (Gleevec, STI-571) to restore molecular remissions and chimerism in patients with BCR-ABL-positive CML with minimal residual disease (MRD) post allogeneic BMT/ SCT [abstract no. 665]. Blood 2002 Nov 16; 100 (Pt 1): 177a-8a
76. Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002 May 15; 99 (10): 3861-2
77. Ullmann AJ, Beck J, Kolbe K, et al. Clinical and laboratory evaluation of patients treated with STI-571 (Gleevec™) after allogeneic and syngeneic stem cell transplantation with relapsed Philadelphia chromosome-positive leukemia [abstract no. 1685]. Blood 2001 Nov 16; 98 (Pt 1): 401a
78. Soiffer RJ, Galinsky I, DeAngelo D, et al. Imatinib mesylate (Gleevec) for disease relapse following allogeneic bone marrow transplantation [abstract no. 1682]. Blood 2001 Nov 16; 98 (Pt 1): 400a
79. Pfeifer H, Wassmann B, Scheuring U. et al. ST1571 (Glivec) in the treatment of patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation [abstract no. 0240]. Bone Marrow Transplant 2002 Mar; 29 Suppl. 2: S34
80. Miller CB, Smith BD, Gore SD, et al. Imatinib (STI-571) for treatment of relapse after stem cell transplantation (SCT) [abstract no. 1683]. Blood 2001 Nov 16; 98 (Pt 1): 400a-1a
81. Liesveld JL, Nichols D, Ifthikharuddin JJ, et al. Use of imatinib mesylate in CML patients autografted in the pre-imatinib mesylate era: a single center experience [abstract no. 5471]. Blood 2002 Nov 16; 100 (Pt 2): 473b
82. Deininger MWN, Schleuning M, Sayer H-G, et al. Allografting after imatinib therapy. No evidence for increased transplant-related mortality and favorable result in patients transplanted in remission. A retrospective study by the EBMT. [abstract no. 3097] Blood 2003; 100 (Pt 1): 783a
83. Rosti G, Trabacchi E, Bassi S, et al. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003 Mar; 88 (3): 256-9
84. O'Dwyer ME, Mauro MJ, Kuyl JM, et al. Preliminary evaluation of the combination f imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML [abstract no. 3513]. Blood 2001 Nov 16; 98: 846a
85. O'Brien S, Vallance SE, Craddock C, et al. PEGIntron and ST1571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia [abstract no. 3512]. Blood 2001 Nov 16; 98: 846a
86. Druker BJ, Kantarjian HM, Talpaz M, et al. A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML) [abstract no. 3511]. Blood 2001 Nov 16; 98: 845a-6a
87. Cornelissen JJ, Verhoef GEG, Straetmans N, et al. A dose-escalating phase I/II study of imatinib (Glivec) and cytarabin in first chronic phase chronic myeloid leukemia. Blood 2002 Nov 16; 100 (Pt 1): 95a
88. Hocchaus A, Fischer T, Brummendorf TH. Imatiuib (Glivec®) and pegylated interferon α2a (Pegasys®) I/II combination study in chronic phase chronic myelogenous leukemia (CML) [abstract no. 616]. Blood 2002; 100 (Pt 1): 164a-5a
89. Martine G, Philippe R, Michel T, et al. Imatinib (Gleevec®) and cytarabine (ARA-C) C) is an effective regimen in Philadephia (Ph)-positive chronic myelogenous leukaemia (CML) chronic phase (CP) patients (pts) [abstract no. 351]. Blood 2002; 100 (Pt 1): 95a
90. Mauro MJ, O'Dwyer ME, Stone RM, et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML [abstract no. 617]. Blood 2002; 100 (Pt 1): 165a